GSK (GSK) Commits $800M+ to Expand Biologics Manufacturing in Pe

GSK plans to invest over $800M to expand its operations in Upper Merion Township, Pennsylvania, creating 300 new jobs and retaining 4,500 existing ones. The expansion, set to begin in 2027, will establish a biopharmaceutical innovation and manufacturing hub. This is GSK's second major expansion in Pennsylvania since October 2024, totaling nearly $1.7B in investments. The company will receive tax benefits through state programs.

GSK plans to invest over $800 million in a biopharma hub in Pennsylvania, creating 300 jobs. The state announced the investment, which is expected to boost the local economy and the company's operations.

GSK plans to invest over $800M to expand operations in Montgomery County, Pennsylvania, adding 300 jobs over five years. The company already employs 4,500 full-time workers in the state.

GSK's ViiV Healthcare reported that its long-acting HIV treatment, Cabenuva, met the primary endpoint in a Phase IIIb study, showing superior viral suppression compared to daily oral therapy. The CROWN study involved 326 participants with detectable HIV-1. The treatment is not yet approved for this use. Cabenuva is approved in the US and other markets for virologically suppressed patients.

GSK's Tuas facility in Singapore is now the largest vaccine production site after a cumulative investment of S$850 million, including a recent S$300 million expansion. The site will use advanced hepatitis B vaccine technology, enhancing large-scale production. Singapore's Trade Minister highlighted the importance of vaccine preparedness and the country's attractiveness for biopharmaceutical investments.

GSK-owned ViiV Healthcare reported success in a late-stage trial for its HIV treatment Cabenuva. The Phase 3b CROWN trial involved 1,190 participants and met its primary endpoint, showing non-inferiority to current standard of care.